Norgine Ventures completes financing with ImaginAb
ImaginAb, a privately owned biotechnology company based in Los Angeles, USA, is specialised in engineering of antibody fragments. The company’s lead program, 89Zr-Df-crefmirlimab, a PET imaging agent targeting CD8+ T cells, is currently in Phase II clinical trials. ImaginAb has signed a multi-party collaboration agreement with Pfizer, Astra Zeneca and Takeda for furthering the clinical development of the CD8 ImmunoPET technology and is also partnered with companies such as Roche, Merck and Neuvogen regarding use of the CD8+ PET agent in immuno-oncology and therapeutic vaccine clinical trials.
Norgine Ventures provided ImaginAb with a Bond facility in August 2020.